Leap Therapeutics Inc (LPTX) Stock Price, Quote & News

Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 714 0360

Website: www.leaptx.com

Address:

47 Thorndike Street, Suite B1-1, Cambridge, United States

beforethedeluge Jun. 24 at 2:38 AM

$LPTX The only thing you need to hear about this company is that GILD who owns 14% of the stock and knows everything that is going on under the hood, showed no interest in DKN. What more do you need to know? The final stage of the testing will only show deterioration. Onsi knows this and decided to no longer fund it while declaring they had met their endpoints (which they have not.) This might rank up there with the famous "pivot speech" in January.

1 · Reply

TD123 Jun. 24 at 12:25 AM

$LPTX leap is not going bankrupt or closing their doors. They will do a reverse stock split and find financing by issuing out millions of shares to a financial institution. At the very least they will put DKN-01 to the side and promote FL-501. All existing shareholders will be wiped out. There will be new paid pumpers pushing FL-501 to retail and the cycle continues while Onsi and the board of directors continue to cash in making 1.5 million every year.

1 · Reply

RushingPatience Jun. 23 at 10:34 PM

$LPTX I struggle to understand the price action given the 51 mio volume traded. anyway, been here for so long, aint no point in selling now.

1 · Reply

Walter100 Jun. 23 at 10:17 PM

$LPTX COO and Chief Medical Officer being let go as per 8-K. In June and July end respectively.

1 · Reply

Lara50 Jun. 23 at 10:15 PM

$LPTX will be 20 cents before the end of the week, what a major shame this company is.

1 · Reply

100K2022 Jun. 23 at 10:13 PM

$LPTX smoked!

0 · Reply

Walter100 Jun. 23 at 10:09 PM

$LPTX Cash $23.3 million as of May 31, 2025 before $3.2 million severance cost.

0 · Reply

BreakoutBullz Jun. 23 at 9:16 PM

Have a great evening, everyone! 🔥💰🎯 See you on tomorrow at 4 AM ET! 🕓 Some of our plays from today! $IBO $INDP $HCAI $LPTX $CURR

0 · Reply

wallstreetcarnival Jun. 23 at 8:20 PM

$LPTX labspycho was right all the time. We all should have sold a long time . Don't listen to Walter.

1 · Reply

Mounting_Mayhem Jun. 23 at 8:05 PM

$LPTX Taking bets for the adviser to spend 9 months evaluating the "strategic" options and then finally recommending shutting up shop and returning remaining cash to shareholders 😂

0 · Reply

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

May 13, 2025, 7:00 AM EDT - 5 weeks ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 2 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 2 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Mar 31, 2025, 1:42 PM EDT - 3 months ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 26, 2025, 1:29 PM EDT - 3 months ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 7:05 AM EDT - 3 months ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:00 AM EDT - 3 months ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Jan 28, 2025, 7:00 AM EST - 5 months ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 6, 2025, 7:01 AM EST - 6 months ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:00 AM EST - 6 months ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 7 months ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 7 months ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 7:00 AM EDT - 9 months ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Aug 12, 2024, 7:00 AM EDT - 11 months ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Leap Therapeutics Announces $40 Million Private Placement

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 16, 2024, 5:05 PM EST - 1 year ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 3, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Dec 11, 2023, 4:05 PM EST - 1 year ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Nov 21, 2023, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

May 25, 2023, 5:10 PM EDT - 2 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 15, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Jan 17, 2023, 8:00 AM EST - 2 years ago

Leap Therapeutics Acquires Flame Biosciences

Jan 11, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Nov 21, 2022, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2022 Financial Results

Nov 7, 2022, 8:05 AM EST - 2 years ago

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Oct 17, 2022, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Oct 12, 2022, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Sep 4, 2022, 6:05 PM EDT - 3 years ago

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

Aug 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

Jul 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

ONC

beforethedeluge Jun. 24 at 2:38 AM

1 · Reply

TD123 Jun. 24 at 12:25 AM

1 · Reply

RushingPatience Jun. 23 at 10:34 PM

$LPTX I struggle to understand the price action given the 51 mio volume traded. anyway, been here for so long, aint no point in selling now.

1 · Reply

Walter100 Jun. 23 at 10:17 PM

$LPTX COO and Chief Medical Officer being let go as per 8-K. In June and July end respectively.

1 · Reply

Lara50 Jun. 23 at 10:15 PM

$LPTX will be 20 cents before the end of the week, what a major shame this company is.

1 · Reply

100K2022 Jun. 23 at 10:13 PM

$LPTX smoked!

0 · Reply

Walter100 Jun. 23 at 10:09 PM

$LPTX Cash $23.3 million as of May 31, 2025 before $3.2 million severance cost.

0 · Reply

BreakoutBullz Jun. 23 at 9:16 PM

Have a great evening, everyone! 🔥💰🎯 See you on tomorrow at 4 AM ET! 🕓 Some of our plays from today! $IBO $INDP $HCAI $LPTX $CURR

0 · Reply

wallstreetcarnival Jun. 23 at 8:20 PM

$LPTX labspycho was right all the time. We all should have sold a long time . Don't listen to Walter.

1 · Reply

Mounting_Mayhem Jun. 23 at 8:05 PM

$LPTX Taking bets for the adviser to spend 9 months evaluating the "strategic" options and then finally recommending shutting up shop and returning remaining cash to shareholders 😂

0 · Reply

Aboni Jun. 23 at 7:38 PM

$LPTX i dont know if its better for the company to release news or not, i cant remember the last time that, they made a PR and the stock go up. Im still bullish, but man its really hard with this one

1 · Reply

IwM Jun. 23 at 7:26 PM

$LPTX respectfully, Doug can be shot to the moon New leadership is the only thing to move this thing up Pathetic

2 · Reply

StawkTua Jun. 23 at 7:24 PM

$LPTX Wait for the mid to low 0.20s, buy and then wait for 6-15x run, or churn outsized moves with no news like it’s been doing for the last ~3 years.

0 · Reply

Walter100 Jun. 23 at 7:20 PM

$LPTX We went bankrupt a few minutes ago. 😂😂 That’s what they want you to believe.

0 · Reply

100K2022 Jun. 23 at 7:17 PM

$LPTX F this I’m out! Good luck ya’ll

1 · Reply

Walter100 Jun. 23 at 7:17 PM

$LPTX FUD propoganda in coming out in full swing to support the short attack .

1 · Reply

Lara50 Jun. 23 at 7:12 PM

$LPTX is liquidating, desperately trying to find someone to sell their stuff too. market was expecting better news, not them worsening. company was badly ran, and now they are in this position.

1 · Reply

mikestonk Jun. 23 at 7:10 PM

$LPTX What a kick in the nuts…such a disaster

0 · Reply

Walter100 Jun. 23 at 7:10 PM

$LPTX I see thd price action as clear intimidation to retail weak hands to sell. This is ridiculous. Even a fire sale will get us $1.

1 · Reply

Walter100 Jun. 23 at 7:06 PM

$LPTX $0.32 and 51 million shares traded. Seriously?

0 · Reply

deano361 Jun. 23 at 6:51 PM

$LPTX o/s traded today once again. Amazing!

0 · Reply

kamikaze_andy Jun. 23 at 5:23 PM

$LPTX “transformational year” ringing in my ears all day . I do hope they package up everything & can sell. But honestly, Doug behaved like a slimy bozo.

1 · Reply

Market Cap	15.62M
Revenue (ttm)	0.00
Net Income (ttm)	-67.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	52,835,703
Avg Vol	1,395,138
Day's Range	N/A - N/A
Shares Out	41.44M
Stochastic %K	0%
Beta	-0.23
Analysts	Hold
Price Target	$1.25